Therapeutic Vaccination of Chronic Hepatitis C Nonresponder Patients With the Peptide Vaccine IC41
To access this article, please choose from the options below
Conflicts of interest: C.S.K. is an employee of Intercell AG. H.W., M.P.M., H.B., H.H., T.B., and S.Z. have received consultancy fees from Intercell AG.
C.K.L. and H.W. contributed equally to this work.
Supported by research grants from Intercell AG (to H.W., T.B., H.H., G.C., S.Z., and H.B.) and by a generous grant from the Austrian Fond zur Förderung der Forschung (FFG).
PII: S0016-5085(08)00346-6
doi:10.1053/j.gastro.2008.02.058
© 2008 AGA Institute. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Therapeutic Vaccination for Hepatitis C: Can Protective T-Cell Responses Be Restored After Prolonged Antigen Exposure?

